CHICAGO and NASHVILLE, Tenn. – May 13, 2022 – GTCR, a leading private equity firm, announced today that it has made a majority investment in PathGroup Holdings LLC (“PathGroup” or the “Company”) in partnership with founder and CEO Ben Davis, MD and the PathGroup management team, who have made a substantial reinvestment in the Company. As part of GTCR’s Leaders Strategy™, Dave King, the former Chairman and CEO of Labcorp, will join the PathGroup Board as Chairman, partnering with Dr. Davis and GTCR to further invest in PathGroup’s capabilities across the pathology, molecular, and genetic diagnostics modalities. Pritzker Private Capital and Vesey Street Capital Partners will also be retaining a minority ownership stake in the Company alongside GTCR and the PathGroup management team.
Click here to read the full press release.